This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Classification of retinoblastoma

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Retinoblastoma can be:

  • familial or sporadic
    • around 94% of newly diagnosed retinoblatomas are sporadic (without a family history of the disease)
    • the remaining 6% are familial
  • bilateral or unilateral
    • the disease is unilateral in 70-75% of patients and bilateral in the remaining
  • heritable or non heritable
    • around 40-50% of cases are hereditary
      • results from germline mutations which can be either a new-onset germline mutation (negative family history) or from a mutation transmitted as an autosomal trait (1,2)
      • typically inherited in an autosomal dominant pattern (2)
      • can manifest as either unilateral or bilateral disease (1)
    • 50-60% are non hereditary (1)
      • occurs secondary to somatic mutations (2)
      • the tumour always manifests as unilateral disease (1)

All three classification schemes are interrelated (1).

  • bilateral and familial retinoblastomas results from a germline mutation and are thus considered heritable tumours (3)
  • unilateral sporadic disease is usually not considered as a heritable condition
    • around 10-15% of unilateral sporadic cases have a germline mutation while the remaining are caused by somatic mutations (1,3)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.